Stanley Joewono is an Indonesia social media influencer and exercise enthusiast. Diagnosed with thalassemia at just 8 months ...

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

A next generation Snap Cartridge, part of the Gazelle™ S-10B Hb Variant Test Multipack, will simplify sample preparation so ...

ZUG, Switzerland and BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CRSP), a biopharmaceutical company focused on ...

Members of the NIH’s recently reconstituted scientific management review board had strong reactions to congressional ...

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported third quarter results and business highlights for the quarter ended September ...

These three emerging technology leaders are pioneering quantum computing, gene editing, and electric aviation.

Swiss CDMO Lonza is bulking up its bioconjugation manufacturing digs with two new multicustomer suites and 200 new jobs at ...

Known as Zynteglo in Europe where it is approved to treat the rare blood disorder beta-thalassemia, the gene therapy has been given the all-clear by bluebird’s scientists after reviewing the ...

Newborn screening is a fundamental right for every child, crucial for early diagnosis and intervention of preventable ...

The Cas nuclease market is on an upward trajectory, forecasted to grow from $2.75 billion in 2023 to $3.27 billion in 2024, at a CAGR of 18.9%. Key drivers include the rapid advancements in genome ...

Shares of Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) have earned a consensus rating of “Moderate Buy” from the ...